Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection
Molnupiravir is a novel antiviral agent for coronavirus disease 2019 (COVID-19) treatment. Warfarin is an oral anticoagulation agent with difficult management due to drug interactions. Here, we describe a case of international normalized ratio (INR) prolongation in a patient who administrated warfar...
Main Authors: | Hikari Mizutani, Tetsuro Koide, Takashi Omura, Kumiko Ito |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Journal of Family Medicine and Primary Care |
Subjects: | |
Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=11;spage=7463;epage=7465;aulast=Mizutani |
Similar Items
-
Molnupiravir: A new candidate for COVID‐19 treatment
by: Fariba Pourkarim, et al.
Published: (2022-02-01) -
Warfarin interactions: a letter to editor
by: Sayyed Majid Sadrzadeh, et al.
Published: (2019-10-01) -
Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023-10-01) -
Case report on interaction of warfarin with herbal medicine “kadha”
by: Rajendra Kumar Premchand, et al.
Published: (2021-05-01) -
Safety and Effectiveness of Molnupiravir in Covid-19 Treatment: A Rapid Review
by: Mohammadreza Mobinizadeh, et al.
Published: (2022-10-01)